PI-103

Catalog No.S1038

PI-103 Chemical Structure

Molecular Weight(MW): 348.36

PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 33 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.
Features The first potent, synthetic mTOR inhibitor.
Targets
p110α [3]
(Cell-free assay)
p110β [3]
(Cell-free assay)
p110δ [3]
(Cell-free assay)
p110γ [3]
(Cell-free assay)
DNA-PK [3]
(Cell-free assay)
2 nM 3 nM 3 nM 15 nM 23 nM
In vitro

PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SK-N-BE MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKwMVgh|ryP MUeyOE81QC95MjDo NV\5NJo5cW6mdXPld{B1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdHnvckBwdiCQQjDj[YxtKGe{b4f0bC=> MVuyOlIzPDZ6MR?=
SH-SY5Y M1LBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrsdo15OC16IN88US=> NFe5RVAzPC92OD:3NkBp MoL3bY5lfWOnczD0bY1mNSCjbnSgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7obYJqfGmxbjDvckBPSiClZXzsJIdzd3e2aB?= MUWyOlIzPDZ6MR?=
SH-SY5Y  MXnBdI9xfG:|aYOgRZN{[Xl? MVOxJO69VQ>? NV;0V2tbOC53LUK0JIg> MknFd4Vve2m2aYrld{Bv\XW{b3LsZZN1d22jIHPlcIx{KHSxIHTvfI9zfWKrY3nuMYlv\HWlZXSgZZBweHSxc3nz M3zDdlI3OjJ2Nkix
G 35 SC NXzFOol3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPQNmcxNjB3LUKwJO69VQ>? NF7zSHozPC95MjDo M3z0UGROW09? Mlz5bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MlnoNlYyOjF{NUG=
G 38 SC M3v0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrJR5ljOC5yNT2yNEDPxE1? MoqwNlQwPzJiaB?= M{n5W2ROW09? NHTLV3RqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 NYjIU3FTOjZzMkGyOVE>
G 40 SC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXywMlA2NTJyIN88US=> M1K4dlI1Nzd{IHi= Mlr3SG1UVw>? M1fJOYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NWLKVG9TOjZzMkGyOVE>
G 35 DC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\jSFAvODVvMkCg{txO NX7FWm1HOjRxN{KgbC=> M1f6bmROW09? M{\JeIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? Mn\wNlYyOjF{NUG=
G 38 DC MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjV[lgxNjB3LUKwJO69VQ>? NE[5cnQzPC95MjDo NVPEXWZFTE2VTx?= MlTwbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MYmyOlEzOTJ3MR?=
G 40 DC Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuwMlA2NTJyIN88US=> NGW5R5MzPC95MjDo NWrmeXpDTE2VTx?= NHi2PGRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 M1;HPVI3OTJzMkWx
RD NYXWRZNYSXCxcITvd4l{KEG|c3H5 NEnqbXQyNzFwNT:yJO69VQ>? MonqO|IhcA>? NHL3O|ZqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? M1SwPVI2PzR7M{e4
TE381.T NFHQTplCeG:ydH;zbZMhSXO|YYm= M3X4ZVEwOS53L{Kg{txO M1KxTVczKGh? MWTpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> NH7KcWMzPTd2OUO3PC=>
RMS13 NH;Ld4FCeG:ydH;zbZMhSXO|YYm= NHXUUnkyNzFwNT:yJO69VQ>? M1zre|czKGh? NVXzXIg6cW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? M4H6fVI2PzR7M{e4
RH30  NHzJfHdCeG:ydH;zbZMhSXO|YYm= M1fNTlEwOS53L{Kg{txO MVy3NkBp NWX6dnl{cW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? NVP6b49HOjV5NEmzO|g>
VJ NU[3botTSXCxcITvd4l{KEG|c3H5 Mmr1NU8yNjVxMjFOwG0> Mnv2O|IhcA>? MnuybY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> NGLVcZgzPTd2OUO3PC=>
HS578T MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYC4bGZrOC1|IN88US=> Mnv2O|IhcA>? MmD3bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MkTHNlU4OjF2MUm=
BT549 NH24PY1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFfwVXcxNTNizszN MkLoO|IhcA>? MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MVmyOVczOTRzOR?=
MDA-MB-231 NYLhSpl2S2WubDDWbYFjcWyrdImgRZN{[Xl? MkSwNE0{KM7:TR?= NV\G[2ZXPzJiaB?= NFu1S2lqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MmrTNlU4OjF2MUm=
MDA-MB-468 NY\Mc5dZS2WubDDWbYFjcWyrdImgRZN{[Xl? MnzWNE0{KM7:TR?= MoG5O|IhcA>? Mk\CbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MVyyOVczOTRzOR?=
MDA-MB-436 NWrlcHh6S2WubDDWbYFjcWyrdImgRZN{[Xl? Mlq5NE0{KM7:TR?= MlrYO|IhcA>? NIL4WIxqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MYCyOVczOTRzOR?=
SUM149PT MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnXGNE0{KM7:TR?= Mn\MO|IhcA>? NEL6UWpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M2jkUVI2PzJzNEG5
MDA-MB-468 NVmxXJNFTnWwY4Tpc44hSXO|YYm= MXKwMlAyNTFyIN88US=> NU\WUnpWOjRiaB?= M{GwfIRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? Mmi2NlU4OjF2MUm=
MDA-MB-231 NGHKNlJHfW6ldHnvckBCe3OjeR?= MYmwMlAyNTFyIN88US=> NX7CZ3g{OjRiaB?= M3rhT4Rwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? NIPOPWszPTd{MUSxPS=>
HS578T MmHuSpVv[3Srb36gRZN{[Xl? NXjxT402OC5yMT2xNEDPxE1? NG\S[YszPCCq MYTkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh M3HrVFI2PzJzNEG5
SW872 Ml\2SpVv[3Srb36gRZN{[Xl? MXmwMlAyNTBwNTFOwG0> MoHVNlQhcA>? MnPCdoVlfWOnczDBT3QheGixc4Doc5J6dGG2aX;uJEhxSUuWKTDhcoQhPEWEUEGgdIhwe3Cqb4L5cIF1cW:wIDjwOGVDWDFrIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= NHT1eHgzPDZ7NU[zNi=>
SW982 M3HSe2Z2dmO2aX;uJGF{e2G7 MUGwMlAyNTBwNTFOwG0> Mn3ONlQhcA>? MkK5doVlfWOnczDBT3QheGixc4Doc5J6dGG2aX;uJEhxSUuWKTDhcoQhPEWEUEGgdIhwe3Cqb4L5cIF1cW:wIDjwOGVDWDFrIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= MmHsNlQ3QTV4M{K=
SW872 NHu1S2dCeG:ydH;zbZMhSXO|YYm= NYrhO|BnOC5yMT2wMlUh|ryP M4fRXVQ5KGh? NG\NSWxqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 M3LHRVI1Pjl3NkOy
SW982 NX70XW06SXCxcITvd4l{KEG|c3H5 NEfmOZIxNjBzLUCuOUDPxE1? MWe0PEBp NUDGd5FWcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MYOyOFY6PTZ|Mh?=
AGS HG MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\iOHRZUUN3ME2wMlY5KMLzIECuNFMyKM7:TR?= M16y[FI1PTl5NEe4
AGS LG NInVVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK0TWM2OD1yLkC1JOKyKDBwMECxJO69VQ>? NVLV[pFZOjR3OUe0O|g>
HGC27 HG MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj1TWM2OD1yLkO4JOKyKDBwMEKyJO69VQ>? M2K2bVI1PTl5NEe4
HGC27 LG NUTOWVFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofRTWM2OD1yLkCyJOKyKDBwMEC0JO69VQ>? MoTDNlQ2QTd2N{i=
MKN45 HG Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSwTHRKSzVyPUGuNFEhyrFiMD6wOVEh|ryP NXrscGJWOjR3OUe0O|g>
MKN45 LG M2DIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7KZVRCUUN3ME2wMlg4KMLzIECuNFMxKM7:TR?= MUiyOFU6PzR5OB?=
NUGC4 HG NYfSc443T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3NTWM2OD1zND6wJOKyKDNwOUGzJO69VQ>? Mm\INlQ2QTd2N{i=
NUGC4 LG NHq3TpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe5RYpKSzVyPUG0MlAhyrFiNT6zNlEh|ryP NGDRdYMzPDV7N{S3PC=>
A549 NUO4WIlSTnWwY4Tpc44hSXO|YYm= NWXxToh7OC5{NT:wMlUwOSEQvF2= M4LaUVI1KGh? MluxbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{dGmpaITsfS=> MWGyOFM2OTR{NR?=
H460 NX3UNFBpTnWwY4Tpc44hSXO|YYm= MoP1NE4zPS9yLkWvNUDPxE1? MW[yOEBp M{PZT4lvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2yrZ3j0cJk> Mn;HNlQ{PTF2MkW=
H661 NW\nbYptTnWwY4Tpc44hSXO|YYm= NEP0XYgxNjJ3L{CuOU8yKM7:TR?= NGDWdlkzPCCq MV\pcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? M3vjPFI1OzVzNEK1
SAS NH3mZYVHfW6ldHnvckBCe3OjeR?= NYrzPXBnOC5{NT:wMlUwOSEQvF2= NICwTXozPCCq NXX6fWgxcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 NEPrWIYzPDN3MUSyOS=>
UT5 MkL0SpVv[3Srb36gRZN{[Xl? M4fsZlAvOjVxMD61M|Eh|ryP NHLMN2EzPCCq NYH2UHZjcW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 M2rHblI1OzVzNEK1
FaDu MoX0SpVv[3Srb36gRZN{[Xl? NFzlfVAxNjJ3L{CuOU8yKM7:TR?= Mnf4NlQhcA>? NUXLPGo2cW6qaXLpeJMhSWu2IIDoc5NxcG:{eXzheIlwdiC|aXfubYZq[2GwdHz5 MlW5NlQ{PTF2MkW=
RD MXfBdI9xfG:|aYOgRZN{[Xl? NI\E[4EyNzFwNT:yJO69VQ>? MlH3O|IhcA>? NELzZoVFVVOR MXjpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 MlyzNlM3QDR7MkW=
TE671 NHPHSWhCeG:ydH;zbZMhSXO|YYm= NXz5XXhCOS9zLkWvNkDPxE1? NUjFeWRVPzJiaB?= NEPibZpFVVOR MmXwbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> M1v5RVI{Pjh2OUK1
RH30  NH\SeoFCeG:ydH;zbZMhSXO|YYm= MnntNU8yNjVxMjFOwG0> NHXCeHk4OiCq M1zqTmROW09? MWXpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 MkPQNlM3QDR7MkW=
RMS13 NYXKb|VTSXCxcITvd4l{KEG|c3H5 M4XvbVEwOS53L{Kg{txO M{TG[FczKGh? MkXHSG1UVw>? MneybY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> MmfjNlM3QDR7MkW=
SUM149PT NIK4R2JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFnOdlMxNjNizszN MkG2O|IhcA>? Mlnv[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ MnjXNlM3ODFyN{S=
MDA-MB-468 NEL6NppE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIjWN2QxNjNizszN NHvTS4Q4OiCq M{O1PYVvcGGwY3XzJIN6fG:2b4jpZ{Bm\m[nY4TzJI9nKFCLM1uvRWtVKHCjdHj3ZZkhcW6qaXLpeI9zew>? Ml\ONlM3ODFyN{S=
MDA-MB-231 NWjPVZFrS2WubDDWbYFjcWyrdImgRZN{[Xl? Mn7mNE4{KM7:TR?= MXO3NkBp Mmq2[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ NIjhPI4zOzZyMUC3OC=>
SY5Y MV;GeY5kfGmxbjDBd5NigQ>? MoWyNU42NzJwNT:1JO69VQ>? MWKyOEBp MnfObY5lfWOnczDHNeKh[2WubD3jfYNt\SCjcoLld5Qh[W6mIHHwc5B1d3Orcx?= Mn22NlM{Pzh|NEG=
SKNBE(2c) NGTRfYVHfW6ldHnvckBCe3OjeR?= M1zKcFEvPS9{LkWvOUDPxE1? MVSyOEBp MVXpcoR2[2W|IFexxsBk\WyuLXP5Z4xmKGG{cnXzeEBidmRiYYDvdJRwe2m| M2nCdVI{Ozd6M{Sx
RD NGDYUHBCeG:ydH;zbZMhSXO|YYm= MVqzJOK2VQ>? NEf5XGEyOiCq MULEUXNQ MV3z[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= MVOyN|MxODhyOR?=
TP5014 NXGyV49USXCxcITvd4l{KEG|c3H5 MV:zJOK2VQ>? M3PF[lEzKGh? MW\EUXNQ NIP0VFh{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NHHvSHEzOzNyMEiwPS=>
HT1080 MorBRZBweHSxc3nzJGF{e2G7 MVOzJOK2VQ>? NGLYZXAyOiCq M{TiUmROW09? NIC3W5h{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> NIHtPIczOzNyMEiwPS=>
A549 M3;6N2Z2dmO2aX;uJGF{e2G7 NELsbowxNTNwMzFOwG0> MXu3NkBp NE\WZ4tqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? NFTkUoYzOzJ3OUW5NS=>
HCC827 MoLRSpVv[3Srb36gRZN{[Xl? NXTLfZd6OC1|LkOg{txO NELGWXQ4OiCq NX7ielVvcW6mdXPld{Bkd22ybHX0[UBld3ewcnXneYxifGmxbjDv[kBxSUuW MWGyN|I2QTV7MR?=
H3122 M4DafmZ2dmO2aX;uJGF{e2G7 M{WyW|AuOy5|IN88US=> MYi3NkBp MmfGbY5lfWOnczDjc41xdGW2ZTDkc5dvemWpdXzheIlwdiCxZjDwRWtV MYCyN|I2QTV7MR?=
TALL-1 NHLjOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPNNgKBkc7:TR?= NYfoU2NzPyCm MXrk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MVqyN|A{QDJ5Mx?=
HPB-ALL NUPVfJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jy[VHjiIoQvF2= MmDEO{Bl MXfk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MlnINlMxOzh{N{O=
DND41 M1HpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL6NgKBkc7:TR?= M1Hsclch\A>? Mor0[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NHXFbVczOzB|OEK3Ny=>
SUP-T1 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;UNVcy6oDLzszN NHn2cGo4KGR? Mkny[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MlXhNlMxOzh{N{O=
PEER MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULRemhOOeLCid88US=> NFrhe5E4KGR? NGX6dJNl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NYDsUm9pOjNyM{iyO|M>
ALL-SIL M3ftd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP4NgKBkc7:TR?= NXO2dXNHPyCm Mni5[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 Mn2zNlMxOzh{N{O=
KE37 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PKdFHjiIoQvF2= NEjXb4w4KGR? NYTqR5R5\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 M2XVSFI{ODN6Mkez
Karpas-45 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jlblHjiIoQvF2= NWHnRYpIPyCm MXfk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NETWO2QzOzB|OEK3Ny=>
RPMI-8402 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jXdlHjiIoQvF2= M4\uZVch\A>? Mn;O[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NYfQVIs4OjNyM{iyO|M>
Jurkat NHnJNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjCWY9oOeLCid88US=> Mn\6O{Bl MnXt[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NFTJcZAzOzB|OEK3Ny=>
MOLT-4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH71bY8y6oDLzszN M3PYZ|ch\A>? MoH1[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MmrnNlMxOzh{N{O=
PF-382 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzjRYJSOeLCid88US=> M4[xRlch\A>? Mnvk[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NU\Nbo1sOjNyM{iyO|M>
CCRF-CEM NEfPOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXuNgKBkc7:TR?= MYC3JIQ> MXXk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M4jUelI{ODN6Mkez
LOUCY MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXRR5ZVOeLCid88US=> MlrCO{Bl MYnk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MUKyN|A{QDJ5Mx?=
MOLT-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjjTGc3OeLCid88US=> MoTlO{Bl M13hVIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MYOyN|A{QDJ5Mx?=
MM1S NULEPYpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTWNE0zKM7:TR?= NVfXZWFYOjRiaB?= M1\LOWlEPTB;MD61JO69VQ>? MXuyNlgzQTJ|NB?=
NCI-H929 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLabo4xNTJizszN NH;mVJYzPCCq MWHJR|UxRTBwMkWg{txO Ml3WNlI5Ojl{M{S=
KMS12-BM  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PZN|AuOiEQvF2= M1fQRlI1KGh? M1nTS2lEPTExvK6yJO69VQ>? NELOcW4zOjh{OUKzOC=>
MDA-MB-436 MWTGeY5kfGmxbjDBd5NigQ>? M{LHPVEh|ryP NYTWbllmOjRiaB?= NXTkXm9VemWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> NVOzUJNDOjJ2OEi1PVA>
SUM149PT NXX4T2x3TnWwY4Tpc44hSXO|YYm= MWCxJO69VQ>? NW[5WZdVOjRiaB?= MVvy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW Mn[5NlI1QDh3OUC=
SUM1315MO2 MojkSpVv[3Srb36gRZN{[Xl? NXjZb25zOSEQvF2= NXG3c|NvOjRiaB?= MYXy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW NHzxTmkzOjR6OEW5NC=>
HCC1937 NIiySFhHfW6ldHnvckBCe3OjeR?= M3\aW|Eh|ryP MmWwNlQhcA>? M4foZZJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= MmDPNlI1QDh3OUC=
HCC827 NIHFdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrpWZpLOC1|IN88US=> NWDYWYNwPzJiaB?= NIfMfYtKSzVyPUCuN{DPxE1? MUOyNVIzODR5NB?=
PC-9  Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPuNE0{KM7:TR?= NX\jbI04PzJiaB?= MkLiTWM2OD1yLkig{txO NUnWb4ZVOjF{MkC0O|Q>
LN229 NVvPNGN6TnWwY4Tpc44hSXO|YYm= M4\xfVEh|ryP MUS0PEBp NXPib|RzcW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= NHXaVIQzOTB4Mkm5Ny=>
U87 NYi2OHh6TnWwY4Tpc44hSXO|YYm= M4nHTlEh|ryP NEHFTFM1QCCq NEjCemFqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w NXrGVXB6OjFyNkK5PVM>
U373 MlHoSpVv[3Srb36gRZN{[Xl? NHOwSZYyKM7:TR?= MkLZOFghcA>? MV\pcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v M3S3XFIyODZ{OUmz
SF767 NVjUWY5qTnWwY4Tpc44hSXO|YYm= MomxNUDPxE1? MmjFOFghcA>? M{DneYlv\HWlZYOgZZV1d3CqYXfvd49u\SCob4LtZZRqd25? NH:4dm8zOTB4Mkm5Ny=>
Mel-Juso NGT6cGVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2HRfVAvODIkgKOxNQKBkc7:TR?= MYO3NkBp MWLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MYCyNVA1QDd6NR?=
518A2  NVHrPYRMS2WubDDWbYFjcWyrdImgRZN{[Xl? Ml\qNE4xOeLCk{Gw5qCK|ryP M{LhOlczKGh? NFr5WJBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NEfXcnozOTB2OEe4OS=>
Mel-Juso  M3rrcGZ2dmO2aX;uJGF{e2G7 NVP6UFBuOC5yMEJihLMy6oDLzszN NHTLclIzPCCq MXTzeZBxemW|c3XzJJBpd3OyaH;yfYxifGmxbjDv[kBxcG:|cHjheIllgWxiaX7vd4l1d2xiMz3rbY5ie2ViZH;3cpN1emWjbTD0ZZJo\XS| NXvOT3BCOjFyNEi3PFU>
518A2 MkDoSpVv[3Srb36gRZN{[Xl? MlfhNE4xODIkgKOx5qCK|ryP NWLse4R{OjRiaB?= NGq3WVd{fXCycnXzd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCyaH;zdIhifGmmeXygbY5we2m2b3ygN{1scW6jc3Wg[I94dnO2cnXhcUB1[XKpZYTz NFTxWJIzOTB2OEe4OS=>
PC3  NFnQNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnJ[XQzPGh? NWHB[WlLT0l3MNMgQUAyODBibl2= NVjRPJpkOjB3NUGwOlE>
U87MG MkPESpVv[3Srb36gRZN{[Xl? NF3IW4IxNjFvMTFOwG0> NFPhV|YzPOLCiXlCpC=> M{LZ[GROW09? MXvpcohq[mm2czDQTVNMNW2nZHnheIVlKHOrZ37hcIlv\w>? MXqxPVY{OzZ6Mx?=
U138MG MXTGeY5kfGmxbjDBd5NigQ>? MkfhNE4yNTFizszN MnvLNlTjiImqwrC= NI\tWlJFVVOR NHzabYlqdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= NXfHe3FHOTl4M{O2PFM>
U118MG MXzGeY5kfGmxbjDBd5NigQ>? MY[wMlEuOSEQvF2= NXHxVFZ6OjUkgJnoxsA> M1\HUGROW09? M1jB[IlvcGmkaYTzJHBKO0tvbXXkbYF1\WRic3nncoFtcW6p NFvUXVYyQTZ|M{[4Ny=>
U87MG M4PJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;td5N6UUN3ME2wMlE1KM7:TR?= M4jsbVE6PTh2MkK3
IGROV-1 M1TBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PXRWlEPTB;MD6wOkDPxE1? MlTyNVk2QDR{Mke=
DETROIT562 NWPSb3J{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDSVmZKSzVyPUCuNVMh|ryP MVGxPVU5PDJ{Nx?=
PC3  NFXSVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPaOVFKSzVyPUCuNVAh|ryP MU[xPVU5PDJ{Nx?=
SKOV-3 MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnVc4NNUUN3ME2wMlEzKM7:TR?= MlrLNVk2QDR{Mke=
HUVEC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\iflhKSzVyPUCuNFgh|ryP NWGzfIt2OTl3OESyNlc>
UCH-1  NGfOdm9HfW6ldHnvckBCe3OjeR?= NEHCXVcxNTVizszN M1z3PIlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiYn;0bEBCU1RiYX7kJI1VV1JiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoqwNVk2Ojh2NEG=
UCH-1  NHP1O5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[1NE4xOS1zMDFOwG0> MVS2JIQ> NVniWmVOcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDkc5NmKGSncHXu[IVvfGy7 NY\k[4s6OTl3Mki0OFE>
UCH-1  M2fXdGFxd3C2b4Ppd{BCe3OjeR?= MnPQNE4yNTFyIN88US=> MXKyOEBp M4XER2ROW09? MYDpcoR2[2W|IHHwc5B1d3Orcx?= NVzWZotROTl3Mki0OFE>

... Click to View More Cell Line Experimental Data

In vivo When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]

Protocol

Kinase Assay:[3]
+ Expand

Enzyme Assays:

Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.
Cell Research:[2]
+ Expand
  • Cell lines: U87MG cells
  • Concentrations: 0.5 μM
  • Incubation Time: 24 hours
  • Method: U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
  • Formulation: 50% DMSO
  • Dosages: 5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 24 mg/mL (68.89 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 348.36
Formula

C19H16N4O3

CAS No. 371935-74-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy PI-103 | PI-103 supplier | purchase PI-103 | PI-103 cost | PI-103 manufacturer | order PI-103 | PI-103 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID